Indolmycin is an antibiotic isolated from various Streptomyces strains that functions by competitively inhibiting the prokaryotic tryptophanyl-tRNA synthetase (IC50 = 30 μM) without significantly affecting the corresponding eukaryotic synthetase. It exhibits antibacterial activity against mupirocin- and fusidic acid-resistant strains of Staphylococci.